<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04380857</url>
  </required_header>
  <id_info>
    <org_study_id>WW-2020-DexSMILE</org_study_id>
    <nct_id>NCT04380857</nct_id>
  </id_info>
  <brief_title>Assessing Dextenza Insert After SMILE Procedure</brief_title>
  <official_title>Assessing the Efficacy of DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert, When Placed Within the Lower Eye Lid Canaliculus in Comparison to Topical Prednisolone Acetate Following Bilateral Small Incision Lenticule Extraction (SMILE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>William Wiley, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cleveland Eye Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This three-month prospective, open-label, single-center, randomized investigator initiated&#xD;
      clinical study seeks to investigate the efficacy of DEXTENZA when placed in the lower&#xD;
      canaliculus (study eye) compared to topical corticosteroids (control eye) following bilateral&#xD;
      SMILE surgery. In addition, the study will evaluate physician assessment of ease of DEXTENZA&#xD;
      insertion&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      4.1 Study Population The study aims to enroll 20 patients undergoing bilateral SMILE.&#xD;
&#xD;
      4.1.1 Inclusion Criteria&#xD;
&#xD;
      A patient's study eye must meet the following criteria to be eligible for inclusion in the&#xD;
      study:&#xD;
&#xD;
        -  Age 18 years and older&#xD;
&#xD;
        -  Scheduled for bilateral SMILE surgery&#xD;
&#xD;
        -  Willing and able to comply with clinic visits and study related procedures&#xD;
&#xD;
        -  Willing and able to sign the informed consent form&#xD;
&#xD;
      4.1.2 Exclusion Criteria&#xD;
&#xD;
      A patient who meets any of the following criteria will be excluded from the study:&#xD;
&#xD;
        -  Patients under the age of 18.&#xD;
&#xD;
        -  Pregnancy (must be ruled out in women of child-bearing age with pregnancy test)&#xD;
&#xD;
        -  Active infectious systemic disease&#xD;
&#xD;
        -  Active infectious ocular or extraocular disease&#xD;
&#xD;
        -  Obstructed nasolacrimal duct in the study eye(s)&#xD;
&#xD;
        -  Hypersensitivity to dexamethasone&#xD;
&#xD;
        -  Patients being treated with immunomodulating agents in the study eye(s)&#xD;
&#xD;
        -  Patients being treated with immunosuppressants and/or oral steroids Patients with severe&#xD;
           disease that warrants critical attention, deemed unsafe for the study by the&#xD;
           investigator&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 4, 2020</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>First eye randomized for either topical prednisolone acetate (control eye) or lower eyelid canaliculus Dextenza insertion (study eye) and the contralateral eye receiving opposite treatment in the OR following SMILE</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in pain</measure>
    <time_frame>Change is being assessed from Day 1 to Month 3</time_frame>
    <description>post-op pain as measure on a scale from 0-10 (ocular pain assessment)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in BCVA</measure>
    <time_frame>Through week 12</time_frame>
    <description>Change in best corrected visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in UCVA</measure>
    <time_frame>Through week 12</time_frame>
    <description>Change in uncorrected visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post op pain management per eye</measure>
    <time_frame>Change is being assessed Day 1, Day 7, Day 30, Month 3</time_frame>
    <description>Proportion of patient callbacks with pain reports</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient preference between groups</measure>
    <time_frame>Change is being assessed Day 1, Day 7, Day 30, Month 3</time_frame>
    <description>As measure by patient symptoms questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Post Procedural Infection</condition>
  <arm_group>
    <arm_group_label>Dexamethazone ophthalmic insert 0.4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethazone ophthalmic insert 0.4 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>topical prednisolone acetate ophthalmic drops</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>topical prednisolone acetate ophthalmic drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone ophthalmic insert 0.4 mg</intervention_name>
    <description>intrcanalicular dexamethasone insert</description>
    <arm_group_label>Dexamethazone ophthalmic insert 0.4 mg</arm_group_label>
    <arm_group_label>topical prednisolone acetate ophthalmic drops</arm_group_label>
    <other_name>Dextenza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years and older&#xD;
&#xD;
          -  Scheduled for bilateral SMILE surgery&#xD;
&#xD;
          -  Willing and able to comply with clinic visits and study related procedures&#xD;
&#xD;
          -  Willing and able to sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under the age of 18.&#xD;
&#xD;
          -  Pregnancy (must be ruled out in women of child-bearing age with pregnancy test)&#xD;
&#xD;
          -  Active infectious systemic disease&#xD;
&#xD;
          -  Active infectious ocular or extraocular disease&#xD;
&#xD;
          -  Obstructed nasolacrimal duct in the study eye(s)&#xD;
&#xD;
          -  Hypersensitivity to dexamethasone&#xD;
&#xD;
          -  Patients being treated with immunomodulating agents in the study eye(s)&#xD;
&#xD;
          -  Patients being treated with immunosuppressants and/or oral steroids Patients with&#xD;
             severe disease that warrants critical attention, deemed unsafe for the study by the&#xD;
             investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Wiley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Eye Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Eye Clinic</name>
      <address>
        <city>Brecksville</city>
        <state>Ohio</state>
        <zip>44141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cleveland Eye Clinic</investigator_affiliation>
    <investigator_full_name>William Wiley, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

